Compare CRAI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | RLAY |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1998 | 2020 |
| Metric | CRAI | RLAY |
|---|---|---|
| Price | $160.05 | $14.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $245.00 | $17.38 |
| AVG Volume (30 Days) | 172.6K | ★ 2.8M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | 20.77 | ★ 31.78 |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | $15,355,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.14 | $324.03 |
| P/E Ratio | $20.23 | ★ N/A |
| Revenue Growth | 9.33 | ★ 53.44 |
| 52 Week Low | $149.96 | $2.30 |
| 52 Week High | $227.29 | $15.00 |
| Indicator | CRAI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 80.08 |
| Support Level | $152.25 | $6.42 |
| Resistance Level | $164.70 | N/A |
| Average True Range (ATR) | 6.04 | 0.86 |
| MACD | 1.19 | 0.52 |
| Stochastic Oscillator | 40.97 | 92.28 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).